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Quality of life of colorectal cancer survivors
in a Ghanaian population
Joseph Yorke2, Emmanuel Acheampong1,3* , Emmanuella Nsenbah Batu1, Christian Obirikorang1,
Francis Agyemang Yeboah1 and Evans Adu Asamoah1

Abstract
Objective: We collected data to evaluate the quality of life of patients who have survived between one and 8 years
from the diagnosis of colorectal cancer.
Data description: We collected quality of life (QoL) data from colorectal patients who were diagnosed between
2009 and 2015 at the Komfo Anokye Teaching Hospital (KATH) and have survived until January 2017. The dataset
consists of patients’ demographic data, clinicopathological characteristics, and QoL data. The validated QoL instruments for data curation was an adopted version of the European Organization for Research and Treatment of Cancer
(EORTC) QLQ-C30 and the EORTC QLQ-CR29. The QLQ-C30 was a 30-item general cancer instrument with 5 functional
subscales, and 9 symptom subscales, whereas the QLQ-CR29 was a 29-item scale that consisted of 3 functional QOL
subscales and 14 symptom subscales, that are associated with colorectal cancer and its treatment. The QoL instrument was coded such that higher scores indicated increased function and better QoL, and higher symptom scores
represent worse symptoms.
Keywords: QoL, Colorectal cancer, EORTC QLQ-C30, EORTC QLQ-CR29
Objective
Colorectal cancer (CRC) from the global perspective is
the third most common malignant neoplasm but was
considered to be rare within the African context [1, 2].
However, recent accumulating evidence has shown that
numerous African countries which were traditionally
recognized as low-risk countries [3, 4] including Ghana
[5], has reportedly increased the rate of CRC. These
trend has previously been confirmed in our previous
work [6] at a major teaching hospital in Ghana. CRC in
these countries represents about 10–50% of all malignant
tumours and has a characteristic unique pattern with an
early age of onset and mostly left-sided tumours [6, 7].
Whereas an increase in survival rates is clearly a great
accomplishment, there are unintended negative consequences with treatments that can potentially reduce
the QoL [8, 9]. Colorectal cancer patients may suffer
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long-lasting pain and reductions in functional and social
well-being irrespectively of the type of treatment including surgery, radiation therapy, and systemic chemo-and
targeted therapy [10]. Therefore, we explored the extent
to which health-related quality of life is affected by CRC
and identified key areas that merit further attention to
improve the quality of survival after CRC is being diagnosed and treated. These effects are explored through
the analysis of survey questions answered by survivors of
colorectal cancer relating to their QoL. The current data
on QoL in CRC patients may improve our understanding of how cancer and its therapy influence the patients’
lives, and how to adapt appropriate treatment strategies.
Part of the results based on this data has been published
in PLOS ONE [11].

Data description
We did our data collection in two parts. First, we did a
retrospective review of the case files of all CRC patients
diagnosed and managed at KATH from 2009 to 2015
and have survived till January 2017, from the Medical
records unit of the surgery department and the Oncology
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Table 1 Overview of data files/data sets
Label

Name of data file/data set

File types
(file extension)

Data repository and identifier (DOI
or accession number)

Data file 1

Table for comparison of QOL based on primary
cancer site

MS Excel file (.xlsx)

https://doi.org/10.6084/m9.figshare.9958673.v1

Data set 1

Colorectal cancer data set (Quality of life)

MS Excel file (.xlsx)

https://doi.org/10.6084/m9.figshare.9958670.v4

Department. We analyzed for information on demographics, clinical and pathological variables including
histological type, grade of tumour and staging based on
the TNM. The type of treatment and follow-up were
also analyzed. Information on age at diagnosis, gender,
tumour location, pathological type of tumour, treatment
modality, family history of CRC, and metastasis were also
reviewed, and the dataset is shown in Table 1. Secondary,
all patients whose information was reviewed were contacted through phone calls, their identity confirmed with
age, name, and hospital identification number and visited
by the research team for interview. In total, 220 cases
were confirmed and included after obtaining their verbal
and written informed consent to partake in the study.
The instrument used to assess QoL in this study were
the European Organization for Research and Treatment
of Cancer (EORTC) QLQ-C30 and the EORTC QLQCR29. The QLQ-C30 was an overall cancer instrument
which contains a 30-items that assess global QOL; 5
functional subscales (emotional, cognitive, social, and
physical role), and 9 symptom subscales (nausea/vomiting, fatigue, appetite loss, diarrhoea, sleep disturbance,
pain and financial influence) [12]. The EORTC QLQCR29 consist 29-items that assess three functional QOL
items (weight anxiety and body image) and (14) symptom
items (mucus and blood in stool, frequency of urination
and stool, dysuria, pain in the abdomen and buttock, feeling bloated, urinary and faecal incontinence, bloated feeling, dry mouth, loss of hair, trouble with taste, sore skin,
and flatulence) that are related to CRC and its treatment
[13]. For both QLQ-C30 and QLQ-CR29, the responses
were scored on a Likert scale of 4 response categories.
Higher functional and global QoL domain scores indicated increased function and better QoL, and a higher
symptom score represents worse symptoms. The dataset for responses to QLQ-C30 and QLQ-CR29 has been
shown in Table 1.

Limitations
The data reflect specific patient population reporting to
KATH. Thus, making it an institutional-based study but
not a population-based study. Also, we assumed, those
who die before a year are likely to have more advanced

disease and more co-morbidities than those who survive
and are likely to report low QoL, however, our data did
not capture such patients. No information was available
from respondents on their QoL prior to being diagnosed
with CRC. In the same way, there was no information
available for non-cancer controls of age, sex and socioeconomic status matched population, which is considered a major limitation of the study.
Abbreviations
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